Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 4Cardiogen (AEDR) literatureEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · Observational2026

SPARC: a structural pathogenicity algorithm for risk classification of hERG variants.

SPARC identifies high-risk hERG variants using a structural pathogenicity score, potentially aiding in the interpretation of genetic testing results.

Read at Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of CardiologyAdd to compare

Where it sits

this study against the rest of the cardiogen (aedr) corpus
0
Preclinical
3
Observational · this one
0
Open-label
1
Randomised
0
Reviews

Summary and findings

This study developed a semi-automated in silico pipeline, SPARC, for predicting the pathogenicity of hERG variants in the KCNH2 gene. The algorithm was applied to 1727 hERG variants, identifying 260 variants as high risk of pathogenicity with a structural pathogenicity score (SPS) of ≥3.25. A subset of these variants was functionally validated using high-throughput automated patch-clamp techniques.

How much of this paper we could read: full text read (0.70). We had a clear abstract, so the summary below closely tracks the paper. What this means →
260 variants identified as high risk of pathogenicity with SPS ≥3.25.n=17272026

Abstract

The authors’ words, as Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology supplied them

Inherited mutations in the KCNH2 gene, which encodes the cardiac hERG potassium channel, are major contributors to arrhythmogenic syndromes such as long QT and short QT syndromes. However, clinical interpretation of the growing number of missense variants - many of which are classified as variants of uncertain significance (VUS) - remains a pressing challenge. Here, we present a semi-automated in silico pipeline for predicting hERG variant pathogenicity, acting as a binary classifier and integrating five structural metrics - residue volume, hydrophobicity, charge, steric clashes, and proximity to pathogenic hotspots - into a composite structural pathogenicity score (SPS) scaled from 1 to 5. Applied to 1727 hERG variants from ClinVar and from a French nationwide cohort, this binary classifier, termed SPARC, identified 260 variants as high risk of pathogenicity with SPS ≥3.25, of which a representative subset from the French cohort was functionally validated using high-throughput automated patch-clamp. Functional phenotyping confirmed the structural predictions, including for several VUS, demonstrating that comprehensive structural scoring can reliably stratify variant pathogenicity. This approach, benchmarked with Alpha Missense and Revel, offers a superior scalable, cost-effective pre-screening tool to guide clinical variant interpretation and prioritization for experimental validation.

Background

This paper addresses the challenge of interpreting inherited mutations in the KCNH2 gene, which are linked to arrhythmogenic syndromes. The increasing number of missense variants complicates clinical decision-making, particularly those classified as variants of uncertain significance (VUS). The study introduces a new computational tool, SPARC, aimed at improving the classification of these variants based on structural metrics.

Methods

The study utilized a semi-automated in silico pipeline to evaluate 1727 hERG variants from ClinVar and a French nationwide cohort. The primary outcome was the identification of high-risk variants based on a composite structural pathogenicity score (SPS) ranging from 1 to 5. A subset of variants was functionally validated through high-throughput automated patch-clamp.

Results

The SPARC algorithm identified 260 variants as high risk of pathogenicity with an SPS of ≥3.25. This classification was benchmarked against existing tools, Alpha Missense and Revel, suggesting improved predictive capabilities. Functional validation confirmed the structural predictions for several VUS, although specific p-values and confidence intervals were not reported.

Interpretation

The findings suggest that SPARC may enhance the classification of hERG variants compared to existing methods, although the clinical significance of the identified variants remains to be fully established. The study's reliance on computational predictions and functional validation in a subset raises questions about the generalizability of the findings. The absence of detailed statistical metrics limits the ability to assess the robustness of the conclusions.

Key findings

  • 260 variants identified as high risk of pathogenicity with SPS ≥3.25 from a total of 1727 hERG variants.
  • SPS scaled from 1 to 5, with higher scores indicating greater risk of pathogenicity.
  • Functional phenotyping confirmed structural predictions for several variants of uncertain significance (VUS).

Limitations

  • Not reported in abstract.
  • Functional validation limited to a representative subset of variants.
  • No detailed statistical metrics provided for the findings.
  • Potential bias from using a single cohort for validation.

Elsewhere in the Cardiogen (AEDR) corpus

BEchocardiographic risk stratification in heart failure with post-capillary pulmonary hypertension: prognostic value of LAVI and TAPSE/PASP.European heart journal. Cardiovascular Imaging · 2026 · HR 1.97, 95% CI 1.41-2.75; P < 0.0001HumanBExpert-Designed Fact Sheets and AI-Based Analysis of Patient Symptoms to Combat Diagnostic Delays in Inherited Metabolic Diseases.Journal of inherited metabolic disease · 2026 · Not reported in abstract.HumanAConsistent Efficacy of Vutrisiran Across Sexes in Transthyretin Cardiac Amyloidosis: Evidence from the HELIOS-B Trial.European journal of heart failure · 2026 · n=654 · Vutrisiran reduced the primary composite endpoint in women (HR 0.59, 95% CI 0.26-1.30) and men (HR 0.71, 95% CI 0.54-0.94; p-interaction = 0.66).Human